Regional Gray and White Matter Metabolite Differences in Subjects With AD, With Subcortical Ischemic Vascular Dementia, and Elderly Controls With 'H Magnetic Resonance Spectroscopic Imaging

Shane MacKay, MD; Dieter J. Meyerhoff, Dr rer nat; Jean-Marc Constans, MD; David Norman, MD; George Fein, PhD; Michael W. Weiner, MD

Objectives To use 'H magnetic resonance spectroscopic imaging to study differences in neuron density (N-acetylaspartate [NAA]), membrane phospholipid metabolites (choline [Cho]), and creatine-containing metabolites (creatine plus phosphocreatine [Cr]) in subjects with Alzheimer's disease (AD), with subcortical ischemic vascular dementia (SIVD), and elderly controls.

Design: Cross-sectional, between groups.

Setting: A Veterans Affairs medical center and university memory clinic.

Participants: Forty elderly subjects with AD (n=14), with SIVD (n=8), and elderly controls (n=18).

Main Outcome Measures: We used 'H magnetic resonance spectroscopic imaging to acquire spectra from a 80x100x17-mm volume superior to the lateral ventricles. Spectra were analyzed from voxels in anterior, medial, and posterior gray and white matter using nuclear magnetic resonance-1 and the results were compared between groups using repeated measures analysis of variance (ANOVA), Tukey's test, and individual Student's t tests.

Results: Using ANOVA, significantly lower levels of NAA/Cho and NAA/Cr and significantly higher levels of Cho/Cr were observed across both gray and white matter voxels in subjects with AD. Using individual Student's t tests, a significantly lower level of NAA/Cho and a higher level of Cho/Cr were observed in the posterior gray matter in subjects with AD. Using ANOVA in subjects with SIVD, significantly lower gray and white matter NAA/Cr levels were observed. Using Tukey's test, the NAA/Cr level was significantly lower in frontal white matter voxels in subjects with SIVD compared with controls.

Conclusions: Our findings in subjects with AD suggest neuron loss in gray matter, axon loss in white matter, and altered Cho metabolism in posterior brain regions. Our findings in subjects with SIVD are consistent with higher levels of creatine-containing metabolites and/or lower levels of NAA in frontal white matter.

(Arch Neurol. 1996;53:167-174)
SUBJECTS AND METHODS

SUBJECTS

Subjects with AD and SIVD were referred from the University of California at San Francisco Memory and Alzheimer Center. All procedures were approved by the university’s Committee on Human Research and all subjects or their guardian provided informed consent. Elderly controls were referred from the medical practices of collaborating geriatricians and recruited by posting fliers at senior citizens centers. All subjects were screened for the following: (1) major medical illnesses such as hypertension, heart disease, and diabetes; (2) major neurological illnesses, such as cortical stroke, head injury with loss of consciousness, seizure disorder, and Parkinson’s disease; (3) alcohol or drug abuse; and (4) major psychiatric illness, such as bipolar disorder or psychosis. Forty elderly subjects participated successfully in the MRSI study. They included 14 patients with AD (six men, eight women; mean age ± SD, 72±7 years; age range, 59 to 82 years), eight patients with SIVD (three men, five women; mean age ± SD, 73±9 years; age range, 51 to 80 years), and 18 elderly control subjects (11 men, seven women; mean age ± SD, 70±5 years; age range, 61 to 80 years). Data from eight of the subjects with AD and 10 of the control subjects were reported previously.

All 14 subjects with AD met the National Institute of Neurological Disorders and Stroke—Alzheimer’s Disease and Related Disorders Association criteria for probable AD. These subjects with AD were receiving thyroid replacement treatment, three had a history of hypertension, and two were receiving antihypertensive medications, although all were normotensive at the time of the procedure. One subject was taking bupropion for depression. Mean (±SD) MMSE score for 13 of the 14 subjects with AD was 14±9, with a range of 0 to 28 (one patient with mild probable AD had a MMSE score of 28; this patient’s diagnosis was based on a gradual, well-documented decline in psychosocial functioning). One subject with AD was too impaired to complete the test.

Eight subjects were diagnosed with SIVD using the criteria of Chui et al. that require decline in two or more areas of intellectual performance and evidence on magnetic resonance imaging (MRI) of at least one infract outside of the cerebellum. Four subjects with SIVD had hypertension, three had diabetes, and two had treated thyroid disease. Subjects with cortical strokes were excluded. Mean (±SD) MMSE score for the subjects with SIVD was 18±6, with a range of 5 to 27.

Eighteen elderly control subjects were screened as described above. One control subject was receiving thyroid replacement therapy, one had mild hypertension, and one had a prior diagnosis of lupus erythematosus that did not involve the central nervous system. All elderly controls scored 28 or more on the MMSE (mean ± SD score, 29±0.8).

When necessary subjects were sedated with 5 to 10 mg diazepam orally or 0.5 to 2 mg lorazepam sublingually for the magnetic resonance examination. Lorazepam was the preferred agent because of its rapid onset when given sublingually and its shorter half-life. Heart rate and oxygen saturation were monitored during the magnetic resonance procedures using a pulse oximeter. Twelve of 14 subjects with AD, eight of eight subjects with SIVD, and five of 18 controls required sedation. Although the use of sedation varied among the three groups, benzodiazepines are not known to affect 'H MRSI metabolites. We previously demonstrated that 20 mg of diazepam had no effect on cerebral magnetic resonance spectroscopic metabolites radioactively labeled with phosphorus 31.

MAGNETIC RESONANCE

All magnetic resonance studies were performed on a body-2-T MRI and magnetic resonance spectroscopic system (Philips Medical Systems, Shelton, Conn). The procedures for MRI and 'H MRSI were the same as previously described. Briefly, magnetic resonance slices were angulated along the canthomeatal line. Nineteen to 23 contiguous sections of 3.1-mm thickness and 0.5-mm section gap repetition time, 3000 milliseconds; echo time, 30 and 80 milliseconds were obtained to cover the entire brain from cerebellum to vertex. The magnetic resonance images were qualitatively evaluated by a board certified neuroradiologist (D.N.) blinded to each subject’s diagnosis. Ventricular dilatation and sulcal widening were each rated as follows: 0, absent; 1, mild; 2, moderate; and 3, severe. Similarly, WMHSs were rated as follows: 0, absent; 1, limited to the tips of the horns of the lateral ventricles and/or periventricular rims; 2, small focal WMHSs in subependymal or subcortical regions; and 3, large or coalescing lesions. After MRI, a 17-mm-thick volume of interest corresponding in location and thickness to the three MRI slices immediately superior to the lateral ventricles was selected for 'H MRSI. The anterior-posterior and left-right dimensions of the 'H MRSI volume of interest were adjusted for every subject according to brain size (typically about 100 by 80 mm, respectively). The position of a typical volume of interest is shown in Figure 1. The 'H MRSI parameters (field of view, 1 mm) and metabolite differences, and WMHSs were scored according to the criteria of Chui et al. to a larger cohort and to compare these differences with findings from a group of subjects with SIVD. Our first a priori hypothesis was that gray matter and white matter NAA/Cho and NAA/Cr levels would be lower in subjects with AD compared with controls, whereas in subjects with SIVD, only differences in white matter metabolites would be observed. Our second a priori hypothesis was that metabolite differences in posterior (parietal) white matter regions would be detectable in subjects with AD compared with controls, whereas fromal white matter changes would be more prominent in subjects with SIVD.
Our third a priori hypothesis was that regional or tissue metabolite differences observed in subjects with AD and subjects with SIVD would occur in proportion to degree of dementia as determined by the Mini-Mental State examination (MMSE).

RESULTS

OVERALL DIFFERENCES IN GRAY AND WHITE MATTER

Our first a priori hypothesis was that, over all nine voxels, NAA/Cho and NAA/Cr levels would be lower in subjects with AD compared with controls; while in subjects with SIVD, only metabolite differences in the bilateral white matter would be observed (Table 1).

Comparing subjects with AD with controls, there was a main effect of group indicating significantly lower levels of NAA/Cho (P=.001) and NAA/Cr (P=.02) and a significantly higher level of Cho/Cr (P=.02) in subjects with AD. We observed no group by tissue-type interaction, indicating that these differences were comparable in the gray and white matter voxels. In Table 1, these are indicated as gray matter plus white matter differences.

Comparing the SIVD group with controls, we found a main effect indicating significantly lower levels of NAA/Cr in subjects with SIVD across all nine voxels (P=.03).
An analysis of group by tissue interaction was not significant (P=.12), however, this result suggested that the difference between groups might be greater in the white matter volumes. This was supported by Tukey’s test, which found significant (P<.05) differences in levels of NAA/Cr between subjects with SIVD and controls only in the white matter.

**REGIONAL WHITE MATTER EFFECTS**

Our second a priori hypothesis was that metabolite differences in posterior (parietal) white matter regions would be detectable in subjects with AD compared with controls, while frontal white matter changes would be more prominent in subjects with SIVD.

**Subjects With AD vs Controls**

Repeated measures ANOVA of white matter metabolite ratios only revealed an effect of group that indicates lower levels of NAA/Cho (P=.005) and NAA/Cr (P=.04) in subjects with AD across all six white matter voxels, consistent with the findings described for the first hypothesis. There was no significant group by region interaction.

To further investigate the effects of individual metabolites on regional metabolite ratios in subjects with AD, we compared the relative patterns of the metabolites in frontal, medial, and posterior white matter voxels using raw signal integrals. In subjects with AD, there was a trend toward a significant NAA region by group effect (P=.07) reflecting a relative reduction in white matter NAA level in subjects with AD, primarily in lower frontal white matter. A significant between-group difference in white matter Cho level was found (P=.05), with the difference caused primarily by higher posterior Cho.

**Subjects With SIVD vs Controls**

A significant group by region (ie, front to back) effect was detected for NAA/Cr (P=.02), reflecting a relative reduction in the NAA/Cr level in frontal white matter voxels in subjects with SIVD vs controls (Table 2). A trend toward a group by region interaction effect was detected for Cho/Cr in subjects with SIVD vs controls (P=.07), and was a result of a lower level of Cho/Cr in frontal white matter in SIVD subjects compared with controls.
Table 2. "A Magnetic Resonance Spectroscopic Imaging Metabolite Levels From Frontal and Posterior White Matter Voxel".

<table>
<thead>
<tr>
<th></th>
<th>Frontal</th>
<th>Medial</th>
<th>Posterior</th>
</tr>
</thead>
<tbody>
<tr>
<td>NAA/Cho</td>
<td>1.3±0.4</td>
<td>2.0±0.8</td>
<td>3.6±0.2</td>
</tr>
<tr>
<td>NAA/Cr</td>
<td>2.1±0.1</td>
<td>2.7±0.2</td>
<td>2.8±0.6</td>
</tr>
<tr>
<td>Cho/Cr</td>
<td>1.4±0.3</td>
<td>1.6±0.4</td>
<td>1.2±0.3</td>
</tr>
</tbody>
</table>

*AD indicates Alzheimer's disease; SIVD, subcortical ischemic vascular dementia; NAA, N-acetylaspartate; Cho, choline-containing metabolites; and Cr, sum of creatine plus phosphocreatine. Values are means±SDs.

Significant group by region effect vs controls by repeated analysis of variance measures.

![Figure 2. White matter N-acetylaspartate and the sum of creatine plus phosphocreatine (NAA/Cr) levels from frontal, medial, and posterior voxels of subjects with Alzheimer's disease (AD), subjects with subcortical ischemic vascular dementia (SIVD), and controls. Values are means±SEs. Asterisk indicates P<.05 vs controls.](image)

Subjects With AD vs With SIVD

A trend toward a group by region effect (P=.06) was seen for white matter NAA/Cho levels because of lower posterior white matter NAA/Cho levels in subjects with AD. This finding is consistent with the hypothesis that brain effects are greater in the parietal white matter in subjects with AD than in medial or frontal white matter.

POSTERIOR GRAY MATTER DIFFERENCES

A post hoc hypothesis was generated from an analysis of data from the first five subjects with AD and seven controls that was published as an abstract. In that report, the NAA/Cho level was significantly lower and the Cho/Cr level was significantly higher in the posterior mesial gray matter of subjects with AD vs controls. Following that analysis, an additional nine subjects with AD and 11 controls were recruited. Metabolite ratios from the posterior mesial gray matter of only these additional subjects are shown in Table 3. Significantly lower levels of NAA/Cho (P<.004) and significantly higher Cho/Cr levels (P=.004) were found in the posterior gray matter of subjects with AD compared with controls using Student's t tests with Bonferroni's correction for the two comparisons. This result confirms our earlier finding.

A similar analysis was conducted using data from our SIVD cohort. Because SIVD appears to preferentially affect frontal white matter, our hypothesis was that no significant differences in posterior mesial gray matter metabolites would be seen between subjects with SIVD and controls (Table 4). The NAA/Cho level was significantly lower in the posterior mesial gray matter voxel in subjects with SIVD vs controls (P<.05), while the Cho/Cr level was significantly higher (P<.02). Similar to the findings in subjects with AD, these results suggest a higher Cho signal in posterior gray matter in subjects with SIVD. A comparison of metabolite levels between subjects with AD and SIVD for this region found significantly lower NAA/Cho levels in subjects with AD but no differences in the other metabolites. Mean regional gray matter NAA/Cho levels in subjects with AD or SIVD and controls are shown in Figure 4. A scatterplot of individual values
The observation of $^1$H MRSI abnormalities in subjects with AD or SIVD compared with controls raised the possibility that metabolite differences between groups could be related to MRI differences. Based on blinded qualitative analysis of MRI, significant differences in mean ($\pm SD$) ventricular dilatation ($P<.05$) were observed in subjects with AD ($1.3 \pm 1.0$), but not in subjects with SIVD ($1.0 \pm 0.8$) compared with controls ($0.2 \pm 0.4$) using Tukey's test. By comparison, mean ($\pm SD$) sulcal widening was not different between subjects with AD ($1.2 \pm 1.3$) and those with SIVD ($1.0 \pm 0.8$) or controls ($0.7 \pm 0.8$). The WMSH severity was significantly greater in subjects with SIVD ($2.4 \pm 0.7$) compared with both subjects with AD ($1.4 \pm 0.9$) and controls ($1.0 \pm 0.8$) ($P<.05$ for both comparisons by Tukey's test). No significant correlations of $^1$H MRSI metabolites and qualitative MRI measures were observed in subjects with AD. Comparison of frontal white matter NAA/Cr levels with qualitative MRI measures in subjects with SIVD revealed significant negative correlations with both ventricular dilatation ($P=.05$) and sulcal widening ($P=.002$), suggesting a relationship between frontal white matter NAA/Cr levels and cerebral atrophy. No relationship between regional $^1$H MRSI ratios and WMSH severity was observed in subjects with SIVD.

**RELATIONSHIP OF MRSI AND DEMENTIA RATINGS**

Our third a priori hypothesis was that regional or tissue metabolite differences observed in subjects with AD or SIVD would occur in proportion to the degree of dementia as determined by the MMSE. Analysis of the data revealed no significant correlations and no trends toward correlations of white matter or gray matter NAA/Cho, NAA/Cr, or Cho/Cr levels with MMSE scores in subjects with AD or SIVD.

Our primary findings were (1) lower levels of NAA/Cho and NAA/Cr and higher levels of Cho/Cr in both gray and white matter in subjects with AD and (2) lower gray and white matter NAA/Cr levels in subjects with SIVD. In subjects with AD, the differences in Cho ratios were most prominent in posterior gray matter voxels. In subjects with SIVD, differences in NAA/Cr levels were most prominent in frontal white matter voxels.

The NAA is an amino acid found exclusively in neurons and their processes and not in glia. The NAA signal appears specific for NAA in cortex, while N-acetylaspartylglutamate contributes slightly to the NAA peak in white matter. Lower levels of NAA have been interpreted to reflect neuron loss. Recently, however, there

**Table 4. $^1$H Magnetic Resonance Spectroscopic Imaging Metabolite Ratios From Posterior Mesial Gray Matter in Subjects With SIVD and Elderly Controls**

<table>
<thead>
<tr>
<th>Metabolite Ratio</th>
<th>Controls (n=18)</th>
<th>SIVD (n=20)</th>
<th>P (t Test)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NAA/Cho</td>
<td>3.3±1.0</td>
<td>2.5±0.6</td>
<td>0.05</td>
</tr>
<tr>
<td>NAA/Cr</td>
<td>2.5±0.5</td>
<td>2.5±0.6</td>
<td>NS</td>
</tr>
<tr>
<td>Cho/Cr</td>
<td>0.8±0.2</td>
<td>1.0±0.2</td>
<td>NS</td>
</tr>
</tbody>
</table>

* SIVD indicates subcortical ischemic vascular dementia; NAA, N-acetylaspartate; Cho, choline-containing metabolites; Cr, sum of creatine plus phosphocreatine; and NS, not significant. Values are means±SDs.

Figure 5. Scatterplot of individual N-acetylaspartate and choline-containing metabolite (NAA/Cho) values in the posterior mesial gray matter in subjects with Alzheimer's disease (AD), subjects with subcortical ischemic vascular disease (SIVD), and controls. Values are means±SEs. Asterisks indicate $P<.05$ vs controls.
have been reports of reversible decreases of NAA levels in multiple sclerosis and carbon monoxide poisoning, implying that neurons were not killed in these cases but rather suffered reversible injury. Our finding of lower levels of NAA/Cho and NAA/Cr in the gray and white matter of subjects with AD is consistent, therefore, with loss or injury to cortical neurons and their axons. Lower NAA/Cr ratios have been reported in the temporal lobes, temporoparietal regions, parietal lobes, and frontal lobes using in vivo proton spectroscopy in subjects with AD. Our previous report found lower levels of NAA/Cho and NAA/Cr in gray matter and lower levels of NAA/Cho and higher levels of Cho/Cr in gray matter of subjects with AD compared with controls using an analysis based on individual Student's t tests. The current findings represent an extension of those findings to a larger cohort, although this is not a replication because subjects from the earlier report were included in our analysis. Our finding of lower NAA/Cho and higher Cho/Cr levels in posterior gray and white matter voxels in subjects with AD is consistent with alterations in levels of choline-containing metabolites that have been reported previously in postmortem studies of subjects with AD. The Cho differences in subjects with AD in the present study were most prominent in posterior gray matter. High numbers of senile plaques and neurofibrillary tangles have been observed in this region along with neurodegeneration in an autopsy study of subjects with AD. It has been hypothesized that "auto-cannibalism" of membrane bilayer phosphatidylcholine may occur in subjects with AD to provide Cho for production of acetylcholine. Phosphatidylcholine is metabolized to glycerophosphocholine (GPC) and then to phosphocholine and free choline. Both GPC and phosphocholine contribute significantly to the Cho peak in MRSI and GPC contributes to the phosphodiester peak in patients with AD. Enzyme kinetic studies support the idea that phosphatidylcholine catabolism rather than slowed metabolism of GPC are responsible for the higher levels of GPC in subjects with AD. Elevation of phosphodiester levels have been shown to correlate with the numbers of senile plaques in tissue samples taken from frontal and temporoparietal regions of subjects with AD. These other authors proposed that the likely sequence of events is (1) degeneration of synaptocytic processes; (2) elevation of membrane phospholipid breakdown products; and (3) appearance of senile plaques. Elevated Cho signal in the gray matter in subjects with dementia may, therefore, provide an in vivo marker for the appearance of senile plaques. Our findings of lower NAA/Cho and higher Cho/Cr levels in subjects with AD are consistent with an elevation of membrane phospholipid breakdown products. Because our analysis of posterior mesial gray matter metabolites excluded subjects who were reported previously, this result is a replication of our earlier finding.

In contrast to the findings in subjects with AD, only the NAA/Cr level was significantly lower in gray and white matter voxels in subjects with SIVD compared with controls. Regional analysis of the data suggests that the effect is strongest in the frontal white matter voxels. The frontal lobes have been shown previously to be one of the regions most affected in vascular dementia. The finding of a lower NAA/Cr level could be caused by a reduction in NAA or an elevation of creatine-containing metabolites. A lower level of NAA in white matter is consistent with loss or injury to axons. Lower levels of NAA/Cr in subjects with SIVD correlated with measures of both ventricular and sulcal atrophy and suggest an association with volume loss. A lower level of NAA/Cr could also be caused by higher Cr-containing metabolites in subjects with SIVD. Our analysis of the relationship between relative Cr signal in frontal, medial, and posterior white matter voxels in subjects with SIVD suggests that the slope of the anterior and posterior Cr gradient is significantly different in subjects with SIVD compared with controls. Higher levels of phosphocreatine have been reported in the frontal lobes of subjects with vascular dementia using 31P-MRSI. In that study, metabolite differences were detected in regions superficial to subcortical lesions such as the WMShs. The authors speculated that this phenomenon might be due to increased glial reactivity and disconnection of cortical neurons causing accumulation of intracellular high-energy phosphates. Since creatine and phosphocreatine are in dynamic equilibrium, however, an increase in phosphocreatine would not be expected to lead an alteration in the 1H MRSI Cr signal observed in this experiment. The severity of WMShs was significantly greater in the SIVD group than in either the AD or control groups. The WMShs have been shown to be associated with higher MRSI metabolite changes in elderly controls and in subjects with AD or SIVD (unpublished data, 1994). Our analysis of the relationship between 1H MRSI metabolite ratios and WMSH severity in subjects with SIVD revealed no significant correlations or trends, suggesting that the observed metabolite differences are not caused by greater WMSh load in the SIVD group.

Our study has several limitations. First is the difficulty of identifying subjects with pure AD or SIVD using clinical diagnostic criteria. Without autopsy results, it is impossible to rule out the existence of degenerative changes in the SIVD cohort. Similarly, three of the subjects with AD had a history of hypertension and may have had some cerebrovascular damage, although all were normotensive at the time of study. A second limitation of our study is the failure to compare metabolite relaxation times between study groups, since the observed metabolite differences could be due solely to differences in metabolism and, for example, in subjects on different medications. Relaxation times were not measured because of the long examination time required for these studies. Another study found no difference in Cr relaxation times between subjects with AD and controls. A more recent study found a significantly longer Cr relaxation time for NAA in a mixed gray and white matter voxel from the frontal lobes of subjects with AD compared with controls while the T2-relaxation times for Cho.
and Cr were not different between groups. A longer NAA \(T_2\)-relaxation time would lead to an apparent increase in the amount of NAA in the sample. This suggests that if the \(T_2\)-relaxation time for NAA was similarly increased in our AD group, the NAA signal measures presented herein would be too high, which would increase the strength of our findings.

A third limitation is that the signal for each of the voxels in our study did not come entirely from gray or white matter. Signal from subcortical white matter contributed to mesial cortical gray matter signal and signal from subcortical gray matter contributed to white matter signal. As a result, it is possible that metabolite differences in the white matter could give the appearance of significant differences in the gray matter. In subjects with AD, where the effect for the NAA/Cho level is greater in white matter than in gray matter, it is possible that the observed difference in the gray matter NAA/Cho level was influenced by the white matter difference. Definitive clarification of this issue requires determination of gray and white matter contribution to each of the nine voxels of each subject in analysis by tissue segmentation of the MRI. The present analysis is the focus of future work by our group.

Notwithstanding these limitations, the results of these measurements indicate that \(1\) H MRSI detects regional and tissue-specific differences in both subjects with AD and those with SIVD compared with controls. These findings support in vitro and neuropathological findings in subjects with AD and those with SIVD and provide in vivo support for theories of disease effects in these dementias.

Accepted for publication September 13, 1995.

This study was supported by the Department of Veterans Affairs Biological Psychiatry Fellowship Program (Dr Mackay); a French Radiological Society Fellowship (Dr Constans); grant MHAZ5401MH56880 from the National Institute of Mental Health, Bethesda, Md (Dr Fein); grant RO1AG10897 from the National Institutes of Health, Bethesda (Dr Weiner); and the Department of Veterans Affairs Medical Research Service, San Francisco, Calif.

We thank Mary Ann Fricker, MSN, Morton Lieberman, PhD, Mariann di Minno, RN, MA, Kate Skinner, MD, and the University of California at San Francisco Memory and Alzheimer’s Center, Rex Jones, Frank Lowry, Craig Van Dyke, MD, Gerald Matson, PhD, Jay Luxenberg, MD, and William Jagust, MD.

Correspondence to the Department of Veterans Affairs Medical Center, Magnetic Resonance Spectroscopy Unit, 4150 Clement St (114M), San Francisco, CA 94121 (Dr Mackay).

REFERENCES


5. Harris G, Links JM, Pearson G, Camargo E. Cortical circumferential profile of


From the Department of Neurology, University of Rogaland (I and Mrs,); Department of Psychosocial Medicine, Hospital of Rogaland (Dr Aarsland); and University of Nebraska, College of Medicine, Omaha, Nebraska, and the University of Chicago, Chicago, Illinois.